INAB IN8bio, Inc.

NASDAQ
$1.10

IN8bio, Inc. (INAB) is expected to report earnings on November 5, 2026, after the market close. The consensus earnings estimate is a loss of $0.57 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +13.4% since its last earnings release on August 6, 2026.

IN8bio Beat Consensus Estimates
Thursday, August 6, 2026 · 4:01 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 5
Thursday · 4:30 PM ET
Earnings Whisper
-
vs ($0.57)
Rev est $3.32M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $1.11

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About IN8bio, Inc.

IN8bio Inc. is a clinical-stage biotechnology company. It focuses on developing therapies for the treatment of cancers, including solid tumors using allogeneic, autologous, and genetically modified gamma-delta T cells. The company's principal candidate includes INB-200, which are in clinical stage. IN8bio Inc. is based in New York.

Sector

Healthcare

Industry

Biotechnology